HTB

HIV Glasgow 2016

International Congress of Drug Therapy in HIV infection (Glasgow 2016), 23-26 October 2016

1000-fold mark-up for drug prices in high-income countries blocks access to HIV, HCV and cancer drugs

Once-daily raltegravir formulation matches twice-daily results in age, gender, race and baseline viral load/CD4 subgroup analyses

Attachment inhibitor GSK-934/BMS-068: 96-week subgroup analysis in treatment-experienced patients

Once-weekly albuvirtide infusion: early results of T-20-like compound

Simplifying HIV treatment: dual therapy works but monotherapy with either boosted-PIs or dolutegravir does not

Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients

Further reports of CNS-related side effects with dolutegravir

Generic PrEP bought online for UK use is validated by drug testing service

Immunology and HIV persistence – implications for a cure

Selected webcasts from Glasgow 2016